1/31/2017

Flumazenil Injection

Reason for the Shortage

- Fresenius Kabi had flumazenil on shortage due to short-term manufacturing delays.
- Mylan Institutional could not provide a reason for the shortage.
- Sandoz discontinued flumazenil injection in 2015.
- West-Ward stated the reason for the shortage is increased demand.

Available Products

- Flumazenil injection, Fresenius Kabi, 0.1 mg/mL, 10 mL vial, 1 count, NDC 63323-0424-10
- Flumazenil injection, Fresenius Kabi, 0.1 mg/mL, 5 mL vial, 10 count, NDC 63323-0424-05
- Flumazenil injection, Mylan Institutional, 0.1 mg/mL, 10 mL vial, 10 count, NDC 67457-0444-10
- Flumazenil injection, Mylan Institutional, 0.1 mg/mL, 5 mL vial, 10 count, NDC 67457-0447-53
- Flumazenil injection, West-Ward, 0.1 mg/mL, 10 mL vial, 10 count, NDC 00143-9783-10
- Flumazenil injection, West-Ward, 0.1 mg/mL, 5 mL vial, 10 count, NDC 00143-9784-10

Estimated Resupply Dates

- All marketed presentations are available.

Updated

Updated January 31, 2017 by Elyse MacDonald, PharmD, MS, BCPS. Created June 15, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.